"The U.S. Food and Drug Administration today cleared a new screening test that predicts a patient's risk of future coronary heart disease (CHD) events, such as heart attacks.
FDA cleared the test for use in all adults with no history of hear"...
(Generic versions may still be available.)
Because thrombolytic therapy increases the risk of bleeding, Streptase, Streptokinase, is contraindicated in the following situations:
- active internal bleeding
- recent (within 2 months) cerebrovascular accident, intracranial or intraspinal surgery (see WARNINGS)
- intracranial neoplasm
- severe uncontrolled hypertension
Streptokinase should not be administered to patients having experienced severe allergic reaction to the product.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/7/2008
Additional Streptase Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.